Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. (PFE), headquartered at The Spiral in Manhattan, New York City, is a leading American multinational pharmaceutical and biotechnology corporation established in 1849 by Charles Pfizer and his cousin Charles F. Erhart. Pfizer stands as one of the world's largest pharmaceutical companies, with annual sales nearing $50 billion, excluding COVID-19 product sales.
Pfizer's core business revolves around the development, manufacturing, and global distribution of prescription drugs and vaccines. Its top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. These products contribute significantly to Pfizer's global sales, with nearly 50% of revenues coming from international markets, and emerging markets playing a crucial role.
In recent news, Pfizer continues to make strides in cancer treatment through its collaboration with Astellas and Merck. A key focus has been on the promising cancer therapeutic combinations involving PADCEV™ (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab), targeting metastatic urothelial cancer. This collaboration underscores Pfizer's commitment to advancing cancer treatments and improving patient outcomes worldwide.
Financially, Pfizer remains robust, continually investing in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs. Strategic partnerships and collaborations further enhance its position in the market, ensuring a steady pipeline of new and effective therapeutic solutions.
With a rich history and a steadfast commitment to healthcare innovation, Pfizer Inc. continues to be a significant player in the pharmaceutical industry, dedicated to improving global health through advanced medical research and groundbreaking therapies.
Pfizer has announced a third-quarter 2024 cash dividend of $0.42 per share, marking the company's 343rd consecutive quarterly dividend. The dividend is payable on September 3, 2024, to shareholders of record as of July 26, 2024. This announcement underscores Pfizer's commitment to returning value to its shareholders.
Pfizer (NYSE: PFE) invites investors and the general public to join a webcast conference call on July 30, 2024, at 10:30 a.m. EDT. The call will discuss the company's Second Quarter 2024 Performance Report. Interested parties can access the webcast and the performance report via Pfizer's investor website. Registration is recommended prior to the event. The call can also be accessed by dialing specific numbers for the United States/Canada and international participants. A transcript and replay will be available on Pfizer's website for 90 days post-event.
Pfizer announced positive results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with relapsed or refractory multiple myeloma. The study reported a median overall survival (OS) of 24.6 months and a median progression-free survival (PFS) of 17.2 months. The overall response rate (ORR) was 61.0%, with a complete response rate of 37.4%.
ELREXFIO has shown deep and durable responses, with a two-year estimated duration of response rate at 66.9%, and 87.9% for those with complete or better responses. Pfizer has received FDA accelerated approval and EU conditional marketing authorization for ELREXFIO. Ongoing studies are exploring elranatamab in various settings, from newly diagnosed to heavily pretreated patients.
Pfizer (NYSE: PFE) has announced that its Phase 3 CIFFREO study, evaluating the mini-dystrophin gene therapy, fordadistrogene movaparvovec, for Duchenne muscular dystrophy (DMD), did not meet its primary endpoint. The trial, involving boys aged 4 to 7 years, aimed to assess improvements in motor function using the North Star Ambulatory Assessment (NSAA) one year post-treatment. Secondary endpoints, including 10-meter run/walk velocity and time to rise from the floor, also failed to show significant differences compared to placebo. Safety profiles were mostly mild to moderate, with serious adverse events being manageable. Pfizer remains committed to monitoring participants and exploring future research directions.
Pfizer invites investors and the public to join a webcast of a discussion with CEO Albert Bourla at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 11:20 a.m. EDT. The webcast will be available on Pfizer's investor website. A transcript and replay will be accessible within 24 hours after the live event and will remain available for at least 90 days. Pfizer continues to advance healthcare through science, aiming to improve lives with innovative medicines and vaccines. For more details, visit Pfizer's website.
Takeda and Pfizer announced positive four-year results from the Phase 3 HD21 trial. The trial evaluated ADCETRIS® (brentuximab vedotin) in combination with chemotherapy for treating newly diagnosed Stage IIb/III/IV classical Hodgkin lymphoma. Conducted by the German Hodgkin Study Group (GHSG), the study showed that the ADCETRIS combination significantly improved progression-free survival (PFS) and had a better safety profile compared to the standard eBEACOPP regimen. The results will be presented at the ASCO and EHA 2024 meetings. After 48 months, the ADCETRIS combination showed a 94.3% PFS rate versus 90.9% for eBEACOPP. Additionally, the ADCETRIS regimen was associated with fewer acute and long-lasting toxicities. Takeda and Pfizer are responsible for regulatory filings and commercialization in different regions.
Pfizer's Phase 3 ECHELON-3 study on ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) showed significant results. The regimen reduced the risk of death by 37% compared to chemotherapy alone, with a median overall survival of 13.8 months versus 8.5 months. The study included 230 patients and will be presented at the 2024 ASCO Annual Meeting. ADCETRIS demonstrated consistent benefits across different levels of CD30 expression and is a standard of care in several lymphomas. Median progression-free survival was 4.2 months for the ADCETRIS regimen compared to 2.6 months for the placebo group. The overall response rate was 64.3% versus 41.5%, and complete response rate was 40.2% versus 18.6%. Adverse events included higher rates of neutropenia, thrombocytopenia, and anemia in the ADCETRIS group.
Pfizer's Phase 3 CROWN trial results showed that 60% of patients with ALK-positive advanced non-small cell lung cancer (NSCLC) treated with LORBRENA (lorlatinib) lived beyond five years without disease progression. These results represent an 81% reduction in risk of progression or death compared to XALKORI (crizotinib). The study also reported a 94% reduction in brain metastasis progression. LORBRENA demonstrated consistent safety profiles, with no new safety signals reported. The findings were presented at the 2024 ASCO Annual Meeting and published in the Journal of Clinical Oncology.
Astellas Pharma Inc. will present new research at the 2024 ASCO Annual Meeting showcasing scientific advancements in its oncology portfolio. The company will share data from pivotal trials across various hard-to-treat cancers like prostate, urothelial, and gastric/gastroesophageal junction cancers. Key highlights include Phase 3 trial data supporting enfortumab vedotin, final overall survival results from the SPOTLIGHT study on zolbetuximab, and post-hoc analyses of the EMBARK trial on enzalutamide. Astellas continues to focus on innovative therapies for cancer patients.
Pfizer announced that Andrew Baum, M.D., will join as Chief Strategy and Innovation Officer, EVP. Dr. Baum brings extensive experience in healthcare, equity research, and global partnerships. He will lead Pfizer's strategic plan, portfolio analysis, and business development activities. Dr. Baum will also chair Pfizer's Portfolio Management Team, focusing on advancing vaccines and medicines.